High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA

被引:195
作者
Janoir, C
Zeller, V
Kitzis, MD
Moreau, NJ
Gutmann, L
机构
[1] UNIV PARIS 06, IRMA, F-75270 PARIS 06, FRANCE
[2] HOP ST JOSEPH, SERV BACTERIOL, F-75674 PARIS 14, FRANCE
关键词
D O I
10.1128/AAC.40.12.2760
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The mechanism of high-level fluoroquinolone resistance was studied in strains of Streptococcus pneumoniae, either selected in vitro or isolated from clinical samples, By using DNA from these high-level-resistant strains, low-level-resistant transformants (MIG of pefloxacin, greater than or equal to 32 mu g/ml; MIC of ciprofloxacin, 4 mu g/ml; MIC of sparfloxacin, 0.50 mu g/ml) were obtained at high frequencies (ca. 10(-2)), while high-level-resistant transformants (MIG of pefloxacin, greater than or equal to 64 mu g/ml; MIC of ciprofloxacin, 16 to 64 mu g/ml; MIC of sparfloxacin, greater than or equal to 8 mu g/ml) were obtained only at low frequencies (ca. 10(-4)), This suggested that mutations in at least two unlinked genes were necessary to obtain high-level resistance, Low-level resistance was associated with ParC mutations (change from Ser to Tyr at position 79 [Ser79Tyr], Ser79Phe, or Asp83Gly). ParC mutations were associated, in high-level-resistant strains and transformants, with alterations in the quinolone resistance determining region of GyrA (Ser84Tyr, Ser84Phe; and/or Glu88Lys), Low-level resistance was shown to be necessary for expression of the gyrA mutations. No mutation in the region corresponding to the quinolone resistance-determining region of GyrB and no alteration of drug accumulation were found.
引用
收藏
页码:2760 / 2764
页数:5
相关论文
共 40 条
[1]   ANTIMICROBIAL RESISTANCE IN STREPTOCOCCUS-PNEUMONIAE - AN OVERVIEW [J].
APPELBAUM, PC .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (01) :77-83
[2]   NEISSERIA-GONORRHOEAE ACQUIRES MUTATIONS IN ANALOGOUS REGIONS OF GYRA AND PARC IN FLUOROQUINOLONE-RESISTANT ISOLATES [J].
BELLAND, RJ ;
MORRISON, SG ;
ISON, C ;
HUANG, WM .
MOLECULAR MICROBIOLOGY, 1994, 14 (02) :371-380
[3]  
BERNARD L, 1994, CLIN MICROBIOL INFEC, V1, P60
[4]   CLONING, SEQUENCING, AND EXPRESSION OF THE DNA GYRASE GENES FROM STAPHYLOCOCCUS-AUREUS [J].
BROCKBANK, SMV ;
BARTH, PT .
JOURNAL OF BACTERIOLOGY, 1993, 175 (11) :3269-3277
[5]  
Cambau E, 1993, Drugs, V45 Suppl 3, P15
[6]   INVITRO ACTIVITY OF SPARFLOXACIN COMPARED WITH THOSE OF 5 OTHER QUINOLONES [J].
CANTON, E ;
PEMAN, J ;
JIMENEZ, MT ;
RAMON, MS ;
GOBERNADO, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (03) :558-565
[7]   INVITRO ACTIVITY OF SPARFLOXACIN, A NEW QUINOLONE ANTIMICROBIAL AGENT [J].
COOPER, MA ;
ANDREWS, JM ;
ASHBY, JP ;
MATTHEWS, RS ;
WISE, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 (05) :667-676
[8]   DNA GYRASE MUTATIONS IN QUINOLONE-RESISTANT CLINICAL ISOLATES OF NEISSERIA-GONORRHOEAE [J].
DEGUCHI, T ;
YASUDA, M ;
ASANO, M ;
TADA, K ;
IWATA, H ;
KOMEDA, H ;
EZAKI, T ;
SAITO, I ;
KAWADA, Y .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) :561-563
[9]   MECHANISMS OF QUINOLONE RESISTANCE IN CLINICAL ISOLATES - ACCUMULATION OF SPARFLOXACIN AND OF FLUOROQUINOLONES OF VARIOUS HYDROPHOBICITY, AND ANALYSIS OF MEMBRANE-COMPOSITION [J].
DENIS, A ;
MOREAU, NJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 (03) :379-392
[10]   INVITRO STUDIES OF CIPROFLOXACIN AND SURVEY OF RESISTANCE PATTERNS IN CURRENT ISOLATES [J].
FERNANDES, CJ ;
ACKERMAN, VP .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1990, 13 (02) :79-91